Clinical Trial

Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 28, 2025 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a multicenter, randomized, open-label, active-controlled clinical trial with a two-period crossover design, aimed at evaluating the efficacy and safety of Efsubaglutide Alfa Injection 3 mg administered Q2W in patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control despite dietary and exercise interventions. The primary endpoint is time in range (TIR; glucose concentration 3·9-10·0 mmol/L) during the period from Week 6 to Week 8 of Efsubaglutide Alfa Injection treatment.
Trial Details
NCT Number NCT06900075
Lead Sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions Type 2 Diabetes
Enrollment 88 participants
Start Date 2025-07-30
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-28